ArticleEuropean journal of neurology2026
Fluoroquinolone-Associated Peripheral and Central Nervous System-Related Disorders: A Large German Claims-Based Cohort Study.
Article in European journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo examine the association between newly prescribed fluoroquinolones (FQ) and the occurrence of polyneuropathy and certain neuropsychiatric events.
methodsGerman statutory health insurance-based cohort study (2013-2019) of patients exposed to FQ compared to different reference antibiotics. Patients with an incident antibiotic prescription were followed up for 365 days after initial dispensing. Outcomes were defined by incident diagnoses of polyneuropathy/other peripheral nervous system-related diseases (PNS), depression/other affective disorders (DEP), mood-related symptoms (MOOD), somnolence/stupor/coma (SSC), and consciousness-related symptoms (CONSCIOUS). Piece-wise exponential additive mixed models adjusted for person-time, age, comorbidities, year, and quarter of cohort entry were applied.
resultsThe outcome-specific cohorts included 10.7-14.3 million antibiotic episodes of which 1.7% had incident PNS, 4.8% DEP, 1.5% MOOD, 0.6% SSC, 0.8% CONSCIOUS. Relative risks for these outcomes ranged from 1.04 to 1.10 for FQ versus reference antibiotics. Stratified by gender and age groups, relative risk for PNS was high in ≤ 39-year-old males (aHR = 1.31 [95% 1.19; 1.45]), for MOOD and CONSCIOUS in 40-69-year-old females (aHR = 1.12 [1.08; 1.15], aHR = 1.14 [1.09; 1.19]) for DEP in ≥ 70-year-old males (aHR = 1.16 [1.14; 1.19]), whereas relative risk for SSC was high in ≤ 39-year-old females (aHR = 1.24 [1.10; 1.40]). FQ-associated PNS was mainly comprised of drug-induced polyneuropathy (aHR = 1.68 [1.58; 1.79]). Relative risks for each endpoint varied by choice of active comparator.
conclusionsFQ episodes were associated with an increased risk for neurological and neuropsychiatric events, especially within the first 92 days after initial dispensing. Risk estimates vary by age and gender subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.